DJSG
BEAM icon

D.J. St. Germain’s Beam Therapeutics BEAM Stock Holding History

D.J. St. Germain’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Hold
3,500
– – ﹤0.01% 352
2026
Q1 		$83.4K Hold
3,500
– – ﹤0.01% 387
2025
Q4 		$97K Buy
+3,500
New +$89.3K ﹤0.01% 404

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

D.J. St. Germain's BEAM Position: Q2 2026 in Review

D.J. St. Germain held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 3,500 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #352.

D.J. St. Germain first reported a position in BEAM in Q4 2025 and has held it in 3 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • D.J. St. Germain held 3,500 shares of Beam Therapeutics worth $120K as of Q2 2026.
  • D.J. St. Germain left its Beam Therapeutics share count unchanged in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of D.J. St. Germain's portfolio in Q2 2026, its #352 holding.
  • D.J. St. Germain first reported a position in Beam Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on D.J. St. Germain's 13F filing for Q2 2026, filed 21 Jul 2026.